MacroGenics reported $63.26M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 538M 300K Sep/2025
AstraZeneca USD 1.55B 1.16B Sep/2025
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Genmab DKK 10M 56M Mar/2025
Geron USD 638.02M 637.38M Sep/2025
Gilead Sciences USD 1.24B 0 Sep/2025
J&J USD 2.41B 584K Sep/2025
MacroGenics USD 63.26M 62.63M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Roche Holding CHF 795.62M 699.54K Dec/2025
Xencor USD 71.34M 46K Sep/2025